Ironwood Pharmaceuticals Inc (IRWD)vsZoetis Inc (ZTS)
IRWD
Ironwood Pharmaceuticals Inc
$3.31
-2.65%
HEALTHCARE · Cap: $544.87M
ZTS
Zoetis Inc
$79.44
-0.10%
HEALTHCARE · Cap: $33.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 2536% more annual revenue ($9.53B vs $361.51M). IRWD leads profitability with a 28.3% profit margin vs 28.0%. IRWD trades at a lower P/E of 5.3x. IRWD earns a higher WallStSmart Score of 69/100 (B-).
IRWD
Strong Buy69
out of 100
Grade: B-
ZTS
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.3%
Fair Value
$32.43
Current Price
$3.31
$29.12 discount
Margin of Safety
+11.8%
Fair Value
$145.86
Current Price
$79.44
$66.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Strong operational efficiency at 68.1%
Revenue surging 158.9% year-over-year
Earnings expanding 1047.0% YoY
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Every $100 of equity generates 82 in profit
Strong operational efficiency at 36.6%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Areas to Watch
Smaller company, higher risk/reward
ROE of -575.0% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Trading at 10.1x book value
2.9% revenue growth
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : IRWD
The strongest argument for IRWD centers on P/E Ratio, Operating Margin, Revenue Growth. Profitability is solid with margins at 28.3% and operating margin at 68.1%. Revenue growth of 158.9% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.
Bear Case : IRWD
The primary concerns for IRWD are Market Cap, Return on Equity, Altman Z-Score.
Bear Case : ZTS
The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.
Key Dynamics to Monitor
IRWD profiles as a growth stock while ZTS is a value play — different risk/reward profiles.
ZTS carries more volatility with a beta of 0.74 — expect wider price swings.
IRWD is growing revenue faster at 158.9% — sustainability is the question.
ZTS generates stronger free cash flow (291M), providing more financial flexibility.
Bottom Line
IRWD scores higher overall (69/100 vs 66/100), backed by strong 28.3% margins and 158.9% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ironwood Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts.
Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?